Trial Profile
A phase I clinical pharmacology study of SJP-0135
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Mar 2018
Price :
$35
*
At a glance
- Drugs SJP 0135 (Primary) ; Brimonidine; Timolol
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Pharmacokinetics
- Sponsors Senju Pharmaceutical
- 07 Mar 2018 Status changed from not yet recruiting to completed.
- 04 Oct 2017 New trial record